The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB
- PMID: 12791771
- DOI: 10.1210/me.2003-0132
The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB
Abstract
We have previously shown that the 16-kDa N-terminal fragment of human prolactin (16K hPRL) has antiangiogenic properties, including the ability to induce apoptosis in vascular endothelial cells. Here, we examined whether the nuclear factor-kappaB (NF-kappaB) signaling pathway was involved in mediating the apoptotic action of 16K hPRL in bovine adrenal cortex capillary endothelial cells. In a dose-dependent manner, treatment with 16K hPRL induced inhibitor kappaB-alpha degradation permitting translocation of NF-kappaB to the nucleus and reporter gene activation. Inhibition of NF-kappaB activation by overexpression of a nondegradable inhibitor kappaB-alpha mutant or treatment with NF-kappaB inhibitors blocked 16K hPRL-induced apoptosis. Treatment with 16K hPRL activated the initiator caspases-8 and -9 and the effector caspase-3, all of which were essential for stimulation of DNA fragmentation. This activation of the caspase cascade by 16K hPRL was also NF-kappaB dependent. These findings support the conclusion that NF-kappaB signaling plays a central role in 16K hPRL-induced apoptosis in vascular endothelial cells.
Similar articles
-
The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation.Mol Endocrinol. 2000 Oct;14(10):1536-49. doi: 10.1210/mend.14.10.0543. Mol Endocrinol. 2000. PMID: 11043570
-
16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells.Mol Endocrinol. 1999 May;13(5):692-704. doi: 10.1210/mend.13.5.0280. Mol Endocrinol. 1999. PMID: 10319320
-
The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation.Mol Endocrinol. 2007 Jun;21(6):1422-9. doi: 10.1210/me.2007-0021. Epub 2007 Apr 3. Mol Endocrinol. 2007. PMID: 17405903
-
16K prolactin induces NF-kappaB activation in pulmonary fibroblasts.J Endocrinol. 2002 Dec;175(3):R13-8. doi: 10.1677/joe.0.175r013. J Endocrinol. 2002. PMID: 12475392
-
Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells.Cancer Res. 2005 Jul 15;65(14):6354-63. doi: 10.1158/0008-5472.CAN-04-4061. Cancer Res. 2005. PMID: 16024638
Cited by
-
New insights in prolactin: pathological implications.Nat Rev Endocrinol. 2015 May;11(5):265-75. doi: 10.1038/nrendo.2015.36. Epub 2015 Mar 17. Nat Rev Endocrinol. 2015. PMID: 25781857 Review.
-
Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors.J Cancer Sci Ther. 2013 Jul 4;5(12):417-426. doi: 10.4172/1948-5956.1000235. J Cancer Sci Ther. 2013. PMID: 25258675 Free PMC article.
-
Sex difference in human diseases: mechanistic insights and clinical implications.Signal Transduct Target Ther. 2024 Sep 10;9(1):238. doi: 10.1038/s41392-024-01929-7. Signal Transduct Target Ther. 2024. PMID: 39256355 Free PMC article. Review.
-
Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis.Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14319-24. doi: 10.1073/pnas.0606638103. Epub 2006 Sep 14. Proc Natl Acad Sci U S A. 2006. PMID: 16973751 Free PMC article.
-
Antiangiogenic gene therapy of cancer: recent developments.J Transl Med. 2004 Jun 25;2(1):22. doi: 10.1186/1479-5876-2-22. J Transl Med. 2004. PMID: 15219236 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials